MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Grows Stake in Eli Lilly and Company (NYSE:LLY)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH grew its holdings in Eli Lilly and Company (NYSE:LLY) by 3.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 70,658 shares of the company’s stock after buying an additional 2,368 shares during the quarter. Eli Lilly and Company makes up about 1.6% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s investment portfolio, making the stock its 27th largest holding. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Eli Lilly and Company were worth $41,188,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Norges Bank purchased a new position in Eli Lilly and Company during the fourth quarter valued at $3,416,206,000. Moneta Group Investment Advisors LLC raised its stake in Eli Lilly and Company by 102,752.2% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after buying an additional 5,440,731 shares during the last quarter. Morgan Stanley raised its stake in Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after buying an additional 3,691,436 shares during the last quarter. Imprint Wealth LLC raised its stake in Eli Lilly and Company by 53,716.8% during the second quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock valued at $175,120,000 after buying an additional 1,747,946 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in Eli Lilly and Company during the fourth quarter valued at $445,944,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY traded down $0.22 during mid-day trading on Friday, hitting $777.96. 3,209,424 shares of the company traded hands, compared to its average volume of 2,972,386. The stock’s fifty day moving average price is $734.06 and its 200-day moving average price is $637.99. Eli Lilly and Company has a one year low of $334.58 and a one year high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market cap of $739.19 billion, a price-to-earnings ratio of 134.13, a price-to-earnings-growth ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.09 earnings per share. Research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LLY shares. Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Barclays boosted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. BMO Capital Markets boosted their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Finally, Morgan Stanley boosted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $689.52.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 34,538 shares of the company’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total value of $21,821,453.78. Following the completion of the transaction, the insider now owns 99,719,884 shares of the company’s stock, valued at $63,004,019,910.04. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 over the last 90 days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.